26 citations
,
July 2012 in “Endocrine Connections” Mitotane changes steroid breakdown, affecting cortisol availability.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
November 2021 in “Evidencia” Young patients using finasteride may have higher risks of anxiety, depression, and suicidal thoughts.
Suppressing ODC activity reduces tumor growth in hair follicles.
January 2012 in “The Journal of Clinical Psychiatry” October 2012 in “Sax's Dangerous Properties of Industrial Materials” January 2016 in “Medicinski Podmladak” Finasteride may increase anxiety in bright spaces.
September 2020 in “Journal of Education, Health and Sport” Most patients on isotretinoin for acne experience mild, dose-related side effects, but the connection to depression or bowel disease is uncertain.
2 citations
,
January 2018 in “Indian Journal of Psychiatry/Indian journal of psychiatry” Methylphenidate can cause hair loss, which stops when the drug is discontinued.
13 citations
,
April 2020 in “European Journal of Dermatology” Apremilast showed mixed results for treating severe alopecia areata.
July 2025 in “SKIN The Journal of Cutaneous Medicine” Ritlecitinib is generally safe for alopecia areata patients over 72 months.
1 citations
,
January 1995 in “Yakubutsu dōtai”
May 2024 in “Actas dermo-sifiliográficas/Actas dermo-sifiliográficas” Effective treatments for trichotillomania include cognitive-behavioral therapy, certain medications, and alternative support tools.
December 2023 in “Melatonin research” Nanocarriers make melatonin more effective and reduce side effects.
December 2025 in “International Journal of Innovative Technologies in Social Science” Ritlecitinib is generally safe for long-term use, with mostly mild side effects.
49 citations
,
September 2015 in “Psychoneuroendocrinology” 5α-reductase affects dopamine receptors linked to sensorimotor gating, which may help understand disorders like schizophrenia.
February 2006 in “Journal of The American Academy of Dermatology” Terbinafine is more effective than itraconazole for toenail fungus, especially in older patients, and debridement improves its effectiveness.
June 2011 in “Pharmacopsychiatry” Finasteride improved symptoms in a psychotic patient, but more research is needed.
6 citations
,
August 1996 in “The Journal of Clinical Endocrinology and Metabolism” MK-386 and finasteride together effectively reduce DHT levels, potentially treating acne and male pattern baldness.
13 citations
,
July 2019 in “Toxicology research” Ethanamizuril is safe for rats at 20 mg/kg feed, but higher doses cause hair loss, organ changes, and liver, kidney, and lung damage.
186 citations
,
December 2011 in “Molecules” Three specific 4-azasteroid-2-oximes showed strong enzyme inhibition, but less than finasteride.
49 citations
,
February 2022 in “Drug Design Development and Therapy” Ritlecitinib shows promise for hair regrowth in alopecia areata patients.
July 2017 in “Nursing2023” Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
October 2014 in “Reactions Weekly” September 2024 in “Dermatologica Sinica” Ponatinib can cause a rare skin reaction that resolves with topical treatment and temporary drug discontinuation.
2 citations
,
October 2022 in “British journal of haematology” A girl with Evans' syndrome had her low platelet count successfully treated with zanubrutinib.
37 citations
,
May 2016 in “JAAD case reports” Oral minoxidil shows promise in treating monilethrix-related hair loss.
February 2026 in “PubMed” Finasteride withdrawal causes anxiety-like behavior in male rats.
April 2012 in “Journal of the American Academy of Dermatology” Clofazimine may be effective for treating ashy dermatosis.
October 2021 in “Dermatology Reports” Tofacitinib, a hair regrowth treatment, may worsen acne.